Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-Dose N-Acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-Dose N-Acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2014

At a glance

  • Drugs Acetylcysteine (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms IFIGENIA
  • Sponsors Zambon SpA
  • Most Recent Events

    • 04 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top